Boston Scientific's selloff is overpricing the WATCHMAN slowdown as a broken growth story when the evidence points to an operating reset. CEO Michael Mahoney's roughly $9 million purchase is the clearest vote yet that management sees a fixable problem, not a franchise in decline. The stock is a contrarian buy here, though not a clean momentum chase, because the business is still growing rapidly while expectations have been cut. The panic has created a gap between the headline narrative and the underlying numbers.
The insider activity is unusually concentrated and points in one direction: buying. Three insiders purchased $9.29 million of BSX shares in the past 14 days, with Mahoney acquiring 186,240 shares on August 3 and no reported insider sales in the recent group. That is not proof that WATCHMAN rebounds immediately, but it is a meaningful signal from the people closest to the operating reset, especially after the company reduced its outlook.
The core financial profile does not resemble a broken medical-device business. Boston Scientific delivered 19.9% year-over-year revenue growth and 55.6% EPS growth, while its 21.5% operating margin and 17.5% net margin show that growth is translating into profits. The TickerSpark Score is 77, led by an 85 Profitability sub-score and a 95 Growth sub-score. At 19.89 times trailing earnings and a PEG of 0.43, the valuation is not demanding for a company still growing earnings at that pace.
Execution has also held up better than the panic suggests. BSX has beaten consensus EPS estimates in each of the last eight reported quarters, including $0.86 versus an expected $0.83 in the latest quarter. Analysts remain broadly constructive, with 37 Buy ratings, six Holds and no Sell ratings in the current consensus. The stock's 47.9% year-to-date decline against a 5.7% gain for healthcare has already done a great deal of damage to expectations, giving even a stabilization in WATCHMAN a chance to matter.
The bearish case has real substance: U.S. WATCHMAN sales were expected to remain flat sequentially in the second and third quarters, while competitive pressure in electrophysiology and delays in other products raise the risk that several growth engines are slowing together. Management also cut 2026 organic revenue growth guidance to 6.5%-8% from 10%-11% and adjusted EPS guidance to $3.34-$3.41 from $3.43-$3.49. Recent analyst target cuts and downgrades confirm that the market is not reacting to a single isolated product wobble.
The restructuring adds another layer of uncertainty, with expected pre-tax costs of $700 million-$800 million. That is a large bill, and the stock remains below its 200-day moving average of $72.19. Still, those risks argue for disciplined sizing rather than abandoning the thesis: the company is cutting costs, preserving its growth platform and seeing insiders buy into the reset. The evidence supports a slowdown that needs fixing, not a collapse that needs escaping.
That leaves BSX as a contrarian accumulation candidate for investors willing to wait for operating proof. We would watch the next WATCHMAN trend update, restructuring savings realization and whether the company can extend its eight-quarter earnings beat streak. A return below the 50-day moving average at $45.92 would weaken the near-term setup, while sustained improvement in WATCHMAN volumes would validate Mahoney's purchase more decisively.
The position belongs in the measured-risk bucket, not as an all-in trade. The guidance cut and restructuring charges are already visible, but the combination of $9.29 million in insider buying, strong underlying growth and a 0.43 PEG makes the panic look excessive. Our take is to buy the reset while the market is still treating it like a thesis break.
